A Glycine-to-Arginine Substitution in the Triple-Helical Domain of Type VII Collagen in a Family with Dominant Dystrophic Epidermolysis Bullosa
Journal of Investigative Dermatology, ISSN: 0022-202X, Vol: 104, Issue: 3, Page: 438-440
1995
- 53Citations
- 15Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations53
- Citation Indexes53
- 53
- CrossRef39
- Captures15
- Readers15
- 15
- Mentions1
- References1
- 1
Article Description
We recently demonstrated strong genetic linkage between the type VII collagen gene (COL7A1) and both the dominant and recessive forms of dystrophic epidermolysis bullosa. In this study, we searched for mutations in dominant dystrophic epidermolysis bullosa using polymerase chain reaction amplification of segments of COL7A1, followed by heteroduplex analysis. Examination of the polymerase chain reaction corresponding to exon 73 revealed a heteroduplex resulting from a G-to-A transition at nucleotide 6127 in the triple-helical domain of COL7A1, which converted a glycine residue to an arginine (G2043R). The dominant dystrophic epidermolysis bullosa phenotype in this family probably arose because of a dominant negative effect of this mutation in COL7A1, resulting in the formation of structurally abnormal anchoring fibrils.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022202X15420834; http://dx.doi.org/10.1111/1523-1747.ep12666033; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0028926566&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/7861014; https://linkinghub.elsevier.com/retrieve/pii/S0022202X15420834; https://dx.doi.org/10.1111/1523-1747.ep12666033; http://linkinghub.elsevier.com/retrieve/pii/S0022202X15420834; http://www.nature.com/doifinder/10.1111/1523-1747.ep12666033; http://www.jidonline.org/article/S0022-202X(15)42083-4/abstract; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.jidonline.org%2Farticle%2FS0022-202X%2815%2942083-4%2Fabstract&rc=0&code=jid-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jidonline.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa-2v5FdT9kc7IARlKxv%2526MAID%253Dndcm7yCQfdCuoIcAtieLwQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLEt1UgI9cIkvA%25253D%25253D%2526ORIGIN%253D562128536%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jidonline.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa-2v5FdT9kc7IARlKxv%2526MAID%253Dndcm7yCQfdCuoIcAtieLwQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLEt1UgI9cIkvA%25253D%25253D%2526ORIGIN%253D562128536%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.jidonline.org%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa-2v5FdT9kc7IARlKxv%26MAID%3Dndcm7yCQfdCuoIcAtieLwQ%253D%253D%26SERVER%3DWZ6myaEXBLEt1UgI9cIkvA%253D%253D%26ORIGIN%3D562128536%26RD%3DRD&acw=&utt=
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know